Bristol Looks To New Abilify Uses But Drops Vinflunine Lead Indication
Bristol is gearing up for new growth for its atypical antipsychotic Abilify (aripiprazole) with a new direct-to-consumer advertising campaign and a series of expanded indications
You may also be interested in...
With FDA's approval of Ixempra (ixabepilone), Bristol-Myers Squibb is poised to launch a novel chemotherapy option that offers a refinement of its successful Taxol and activity in taxane resistant patients
Bristol-Myers Squibb is strengthening its investment in biotech treatments for cancer with its proposed acquisition of Adnexus Therapeutics
Acceptance of Bristol-Myers Squibb's Abilify (aripiprazole) as adjunctive therapy for major depressive disorder may be eased by existing off-label use of the atypical antipsychotic in that market, according to the company